{"entity":{"id":"nct04871282","kind":"trial","name":"A Study of AL102 in Patients With Progressing Desmoid Tumors","aka":["RINGSIDE"],"tldr":"A phase 2/3 trial testing Varegacestat in desmoid tumour, active and no longer recruiting.","summary":"A Study of AL102 in Patients With Progressing Desmoid Tumours is a phase 2/3 interventional study registered as NCT04871282, led by Immunome, and active but no longer recruiting on the registry. Official title: RINGSIDE: A Phase 2/3, Randomised, Multicenter Study to Evaluate AL102 in Patients With Progressing Desmoid Tumours. Planned enrolment is 198 participants (actual). The study started in 2021-09-01 and primary completion is expected in 2025-12-03. No results have been posted on ClinicalTrials.gov.","status":"active","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT04871282","url":"https://clinicaltrials.gov/study/NCT04871282"}],"tags":["ctgov-ingest"],"related":[],"cancers":["desmoid-tumour"],"sections":[],"technologies":[],"targets":[],"drugs":["varegacestat"],"companies":["immunome"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04871282","phase":"2/3","setting":"RINGSIDE: A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients With Progressing Desmoid Tumors","sponsor":"Immunome","started":"2021-09-01","startedType":"actual","enrolled":198,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04871282/","neighbours":{"cancer":[{"id":"desmoid-tumour","kind":"cancer","name":"Desmoid tumour","route":"/cancers/desmoid-tumour/"}],"drug":[{"id":"varegacestat","kind":"drug","name":"Varegacestat","route":"/drugs/varegacestat/"}],"company":[{"id":"immunome","kind":"company","name":"Immunome","route":"/companies/immunome/"}]}}